Fineline Cube

Follow:
14437 Articles
Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems
CompanyDeals

Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems

Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia
CompanyDeals

Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million
Company

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million

Roche's VENTANA TROP2 Device Receives FDA Breakthrough Designation
CompanyMedical Device

Roche’s VENTANA TROP2 Device Receives FDA Breakthrough Designation

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-5635 in Chronic HBV
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-5635 in Chronic HBV

Fosun Pharma's Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar
CompanyDeals

Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar

BeiGene Wins USPTO Ruling Invalidating Pharmacyclics' Patent Claims
Legal / IP

BeiGene Wins USPTO Ruling Invalidating Pharmacyclics’ Patent Claims

AstraZeneca's Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines
Company

AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines

Pfizer's Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact
Company

Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact

United Imaging Healthcare Reports 9.73% Revenue Decline in 2024 Financials
Company

United Imaging Healthcare Reports 9.73% Revenue Decline in 2024 Financials

Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma
CompanyDeals

Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma

Boehringer Ingelheim's Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
CompanyDrug

Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial